Compliance18 September 2026 · 9 min read

EU GMP Annex 1 (2022): a practical contamination control strategy checklist

The 2022 revision of EU GMP Annex 1 made the contamination control strategy (CCS) the backbone of sterile manufacturing. An Annex 1 contamination control strategy is not a single SOP — it is a site-wide, risk-based account of every control that keeps microbes, particles and pyrogens out of the product, and of the evidence that those controls work. This checklist shows what to include and how to keep it current.

What Annex 1 says about the contamination control strategy

The revised Annex 1, “Manufacture of Sterile Medicinal Products”, was published by the European Commission in August 2022 and came into effect in August 2023, with one provision on lyophiliser loading deferred to August 2024. PIC/S adopted the same text, so it applies well beyond the EU — including the UK and the many authorities that follow the PIC/S guide.

Annex 1 requires sterile manufacturers to implement a contamination control strategy across the facility to define all critical control points and assess the effectiveness of all the controls — design, procedural, technical and organisational — and the monitoring measures used to manage risks to medicinal product quality and safety. The strategy is expected to be based on quality risk management and to be actively updated as knowledge improves.

Annex 1 also lists the elements a CCS should consider. They range from plant and process design, premises, equipment, personnel and utilities through raw materials, containers and closures, supplier approval and outsourced services, to process risk assessment, validation, sterilisation, preventive maintenance, cleaning and disinfection, monitoring systems, prevention mechanisms such as trending, investigation and CAPA, and continuous improvement.

Although Annex 1 is written for sterile products, its principles — including a contamination control strategy — are increasingly applied to non-sterile manufacturing too.

How to structure an Annex 1 contamination control strategy

Many first-generation CCS documents were long narratives that summarised existing SOPs. They were hard to review and went out of date quickly. A structure that works better in practice has two parts.

1. A short strategy document

Scope (site, product or line), responsibilities, the risk method used, how the CCS is reviewed, and how it links to the pharmaceutical quality system — deviations, CAPA, change control and management review.

2. A register of contamination hazards and controls

One row per hazard, with four columns that matter:

  • Hazard — the contamination route, for example personnel shedding in Grade A, ingress through a door interlock failure, or bioburden in incoming components.
  • Control — the design, technical or procedural measures that prevent it.
  • Monitoring — how you would know the control was failing: EM points, pressure differentials, utility sampling, gowning assessments.
  • Effectiveness — the evidence and review that shows the control works: trends, media fill results, deviation history.

Add an owner and a risk rating to each row, and reference the SOPs, validation reports and monitoring programmes that hold the detail rather than copying them. That keeps the CCS short enough to review and makes it obvious which documents need to change when a hazard row changes.

The register makes gaps visible. A hazard with a control but no monitoring, or monitoring with no defined review, is exactly what an inspector will find.

The CCS checklist: area by area

Facility and equipment

  • Cleanroom grades, airflow, pressure cascades and room qualification status documented and current.
  • Barrier technology (RABS or isolator) justified, with decontamination and glove integrity controls.
  • Preventive maintenance and requalification frequency based on risk.

Personnel

  • Gowning qualification before Grade A/B access, with periodic requalification.
  • Aseptic technique training and behaviour in the cleanroom covered by the CCS.
  • Operator participation in aseptic process simulation.

Utilities

  • Water for injection, purified water, clean steam, compressed gases and HVAC each with alert and action limits.
  • Sampling plans and trending defined, with action breaches investigated.

Materials, containers and closures

  • Supplier qualification and incoming controls for components that contact the product.
  • Bioburden and endotoxin controls for starting materials where relevant.
  • Container closure integrity assured and tested.

Process and sterilisation

  • Sterilisation cycles validated and each cycle released against defined parameters and indicators.
  • Sterilising filter integrity tested after use, and before use unless a risk-based justification applies (pre-use post-sterilisation integrity testing, PUPSIT).
  • Aseptic process simulation (media fill) design, frequency and acceptance criteria — any contaminated unit is investigated.
  • Hold times, lyophilisation and visual inspection controls covered.

Monitoring and prevention

  • Environmental monitoring programme (viable and non-viable) based on risk, with defined locations and frequencies.
  • Trending, excursion investigation, root cause analysis and CAPA linked to the CCS.
  • Cleaning and disinfection programme, including disinfectant efficacy and rotation.

Keeping the CCS alive

Annex 1 expects the CCS to be reviewed and updated. A static document signed once at the start of the programme will not satisfy an inspector. Build these triggers into your procedure:

  • Periodic review — at a defined frequency, typically aligned with management review.
  • Change control — any change to facility, equipment, process or materials assesses its CCS impact.
  • Deviations and excursions — an adverse EM trend or a failed media fill prompts a review of the related hazard rows.
  • New knowledge — supplier changes, new products or regulatory updates.

Each revision should be versioned and approved, with the previous version superseded rather than overwritten, so you can show an inspector what the strategy said at any point in time.

How inspectors test a contamination control strategy

Inspectors rarely read the CCS front to back. They pick a hazard and follow it. For example: “Show me how you control operator contamination at the filling line.” They then expect to see, quickly:

  1. The hazard row and its stated controls.
  2. Gowning qualification records for the operators on a given batch.
  3. EM results for that shift and location, with any excursions and their investigations.
  4. The current media fill that qualifies the line and those operators.
  5. The batch record showing the controls were in place at the time.

If those records sit in five different binders or systems, the answer takes hours. If they are linked, it takes minutes.

How Swat iQua Suite supports your contamination control strategy

Swat iQua Suite covers the Annex 1 controls for sterile and injectable manufacturing on the same platform as its batch records, laboratory and quality modules.

  • Contamination control strategy records per site, optionally per product version, with a hazard → control → monitoring → effectiveness register. Approval is e-signed with segregation of duties and supersedes the previous CCS of the same scope.
  • Environmental monitoring with a cleanroom register, monitoring points and versioned alert and action limits. An action result opens an excursion; its e-signed disposition raises a deviation and blocks batch release.
  • Gowning qualification recorded with an e-signature, where the assessor cannot assess themselves.
  • Utilities monitoring for WFI, clean steam, compressed air, HVAC and other systems, with versioned limits; an action breach raises a deviation.
  • Aseptic process simulation: versioned protocols, runs where any positive unit means a fail, and a line-qualification gate that blocks aseptic filling without a current passing media fill.
  • Sterilisation cycles with biological and chemical indicator results, QA release with segregation of duties, and filter integrity tests before and after use.
  • Lyophilisation cycles, visual inspection runs (100% or AQL, level recorded) and container closure integrity results — failures raise a deviation and a release blocker.

At batch level, a sterile step cannot start unless the operator holds a current gowning qualification, the cleanroom is ready and qualified, there is no open EM excursion in the room and the filling line has a current passing media fill. The CCS register itself is a controlled document and register; you link its monitoring rows to your EM and utilities programmes through your procedures.

FAQ

Frequently asked questions

Can’t find your answer? Talk to our team — we reply within one business day.

Is a contamination control strategy mandatory under Annex 1?

Yes. The 2022 revision of EU GMP Annex 1 requires manufacturers of sterile products to implement a contamination control strategy across the facility, based on quality risk management, and to keep it updated.

Is the CCS one document or many?

Annex 1 does not prescribe a format. Many sites use a short strategy document plus a hazard and control register that references existing SOPs, validation reports and monitoring programmes, rather than duplicating them.

How often should the CCS be reviewed?

At a defined periodic interval set in your procedures, and whenever a change, a significant deviation, an adverse trend or new knowledge affects contamination risk.

Does Annex 1 apply in the UK?

Yes. The UK adopted the revised Annex 1 as part of UK GMP, and PIC/S member authorities have adopted the same text.

Ready to see Swat iQua Suite in action?

Book a free, personalised demo and see how Swat iQua Suite takes your plants, labs and quality teams from paper to inspection-ready.

Download the brochure →